drugset / Trial / NCT00652496

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

NCT00652496

Phase 2 Completed 249 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

Timeline

Start
2005-01
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.01 % Other
Subject Bimatoprost Other / unclassified 0.015 % Other
Subject Bimatoprost Other / unclassified 0.02 % Other
Subject Bimatoprost Other / unclassified 0.03 % Other